WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ: ALTH) announced today the closing of its previously reported underwritten public offering of 7,750,000 shares of its common stock at the public offering price of $6.30 per share. The Company received net proceeds from the offering of approximately $46.8 million, after deducting underwriting commissions and estimated offering expenses. The Company plans to use the net proceeds from the offering primarily for activities relating to preparations for the potential commercial launch of pralatrexate, clinical and preclinical research and development of pralatrexate, working capital and general corporate purposes.
